REFERENCES

1. Anne-Marie, R. O. S., Jerome M. G, Abnoeal D. B, and Mari-Anne, H., (1996),

‘Psoriasis Response to the Pulsed Dye Laser’, Lasers in Surgery and Medicine,
19(3), pp 331-335.

2. Constance., Th. R. M. Schrander-Stumpel, Liesbeth, S., Leopold M. G. C.,

Truus, D., and Jaap J. P. S., (2005) ‘Kabuki Syndrome: Clinical Data in 20
Patients, Literature Review, and Further Guidelines for Preventive
Management’, American Journal of Medical Genetics, 132A(3), pp 234–243

3. David, M., Akerman, L., Ziv, M., Kadurina, M., Gospodinov, D., Pavlotsky, F.,
& Fishman, P. (2012). ‘Treatment of plaque‐type psoriasis with oral CF101: data
from an exploratory randomized phase 2 clinical trial’, Journal of the European
Academy of Dermatology and Venereology, 26(3), pp 361-367.

4. Deepa, M., Ranganath, B., Gopal, R. K., (2016) ‘Clinical Data Management
Importance in Clinical Research’, Asian Journal of Pharmaceuticals and Clinical
Research, Volume 1, pp 59-62

5. Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S.,
& Zhong, J. (2006). ‘Clinical response to adalimumab treatment in patients with
moderate to severe psoriasis: double-blind, randomized controlled trial and
open-label extension study’, Journal of the American Academy of
Dermatology, 55(4), pp 598-606

6. Gottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D.&
Menter, A. (2004). ‘Infliximab induction therapy for patients with severe
plaque-type psoriasis: a randomized, double-blind, placebo-controlled
trial’, Journal of the American Academy of Dermatology, 51(4), pp 534 -542.

7. Gottlieb, A. B., Strober, B., Krueger, J. G., Rohane, P., Zeldis, J. B., Hu, C. C.,
& Kipnis, C. (2008). ‘An open-label, single-arm pilot study in patients with
severe plaque-type psoriasis treated with an oral anti-inflammatory agent,
apremilast.’, Current Medical Research and Opinion, 24(5), pp 1529-1538.
8. Heiko Traupe, Petra J.M. van Gurp, Rudolf Happle, Jan Boezeman, and Peter
C.M. van de Kerkhof, (1992), ‘Psoriasis Vulgaris, Fetal Growth, and Genornic
Imprinting’, American Journal of Medical Genetics, 42(5), pp 649-654

9. Izet M. Kapetanovic (2011) ‘Drug Discovery and Development – Present and

Future’ Intech Open, Croatia, pp 2-9

10. King-man HO (2010), ‘Psoriasis’, Medical Bulletin, 15(5), pp 10-14

11. Krishnankutty,B. , Bellary, S. ,Kumar, N.B.R., (2012) ‘Data management in

clinical research: An overview’ Indian Journal of Pharmacology 44(2), pp 168-
172.

12. Luis Torres, Marc Levine (2017), ‘Clean Patient Tracker - Using SpotFire
Analytics for Patient Data Cleaning’, PhUse, pp 1-3

13. Mittal, R., Malhotra, S., Pandhi, P., Kaur, I., & Dogra, S. (2009). ‘Efficacy and
safety of combination acitretin and pioglitazone therapy in patients with
moderate to severe chronic plaque-type psoriasis: a randomized, double-blind,
placebo-controlled clinical trial.’ Archives of Dermatology, 145(4), pp 387-393.

14. Robert S. Stern, Md. Sally Zierler, Mph, And John A. Parrish, Md (1982),
‘Methotrexate Used for Psoriasis and the Risk of Noncutaneous or Cutaneous
Malignancy’ Cancer, 50(5), pp 869-872.

15. Soujanya Konda (2015), ‘Use of SAS Reports for External Vendor Data
Reconciliation’, PharmaSUG, pp 1-11

16. Thorat. S. B., S. K. Banarjee, D. D. Gaikwad, S. L. Jadhav, R. M. Thorat (2010),

‘Clinical Trial: A Review’ International Journal of Pharmaceutical Sciences
Review and Research, 1(2), pp 101-106

17. Vicki L. Mahan (2014) ‘Clinical Trial Phases’ International Journal of Clinical
Medicine,5, pp 1374-1383

18. Zangeneh. F. Z and F.S. Shooshtary, (2013) ‘Psoriasis — Types, Causes and
Medication’, Intech, pp 3-25